Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib add-on for immunometabolic depression
NL-OMON56197Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Celecoxib add-on with Placebo add-on (2 arms). Primary endpoint: Mean severity of depression symptoms. Started Sep 2022; status: recruiting.
02
Drugs
celecoxib
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON56197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56197.